Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GELAD Chemotherapy and Radiotherapy for Stage IE/II ENKTCL
NCT02733458Phase 2Completed
- Sponsor
- Xinhua Hospital
- Start
- Mar 2016
- Primary completion
- Apr 2021
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, etoposide, dexamethasone, pegaspargase in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Xinhua Hospital. Started Mar 2016; status: completed.
02
Drugs
gemcitabineetoposidedexamethasonepegaspargase
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02733458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733458.